Literature DB >> 2172395

A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection.

B M Farr1, J M Gwaltney, J O Hendley, F G Hayden, R M Naclerio, T McBride, W J Doyle, J V Sorrentino, D K Riker, D Proud.   

Abstract

The effects of combined intranasal and systemic glucocorticoid steroids on the local inflammatory response, and symptoms due to experimental rhinovirus infection were studied in 45 adults randomized to prophylaxis with either placebo or steroids. Intranasal beclomethasone (168 micrograms twice a day) was begun 4 days before viral challenge and continued 5 days after challenge. Oral prednisone (30 mg twice daily) was given for 3 days beginning 1 day before challenge. During the first 48 h after viral inoculation, nasal obstruction, nasal mucus weights, and kinin concentrations in nasal lavages were lower in steroid recipients, but subsequent increases in these variables in the steroid group resulted in no significant cumulative differences between treatment groups. These data suggest that steroid prophylaxis may suppress nasal inflammation and cold symptoms during the first 2 days in experimental rhinovirus colds.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2172395     DOI: 10.1093/infdis/162.5.1173

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

Review 1.  Treatment of the common cold.

Authors:  S B Mossad
Journal:  BMJ       Date:  1998-07-04

Review 2.  Problems and prospects of developing effective therapy for common cold viruses.

Authors:  S L Johnston
Journal:  Trends Microbiol       Date:  1997-02       Impact factor: 17.079

3.  Nitric oxide inhibits rhinovirus-induced cytokine production and viral replication in a human respiratory epithelial cell line.

Authors:  S P Sanders; E S Siekierski; J D Porter; S M Richards; D Proud
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

Review 4.  Association of rhinovirus infections with asthma.

Authors:  J E Gern; W W Busse
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

5.  Basal salivary cortisol secretion and susceptibility to upper respiratory infection.

Authors:  Denise Janicki-Deverts; Sheldon Cohen; Ronald B Turner; William J Doyle
Journal:  Brain Behav Immun       Date:  2016-01-14       Impact factor: 7.217

6.  Sleep habits and susceptibility to the common cold.

Authors:  Sheldon Cohen; William J Doyle; Cuneyt M Alper; Denise Janicki-Deverts; Ronald B Turner
Journal:  Arch Intern Med       Date:  2009-01-12

Review 7.  The kinin system in rhinitis and asthma.

Authors:  D Proud
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

8.  Rhinovirus stimulation of interleukin-6 in vivo and in vitro. Evidence for nuclear factor kappa B-dependent transcriptional activation.

Authors:  Z Zhu; W Tang; A Ray; Y Wu; O Einarsson; M L Landry; J Gwaltney; J A Elias
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

Review 9.  Corticosteroids for the common cold.

Authors:  Gail Hayward; Matthew J Thompson; Rafael Perera; Chris B Del Mar; Paul P Glasziou; Carl J Heneghan
Journal:  Cochrane Database Syst Rev       Date:  2015-10-13

10.  Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist.

Authors:  Javier Milara; Anselm Morell; Bea Ballester; Celia Sanz; Jose Freire; Xiaozhong Qian; Maggie Alonso-Garcia; Esteban Morcillo; Julio Cortijo
Journal:  Respir Res       Date:  2015-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.